MASSACHUSETTS FINANCIAL SERVICES CO /MA/
Position in RIGL — Rigel Pharmaceuticals Inc
CIK 912938
Boston, MA
Position in RIGL
as of Jun 30, 2026
· filed Aug 3, 2026
Position Value
$1,656,379
+$465,836 QoQ
Shares Held
42,341
-3.8% QoQ
Ownership
0.227%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
#53
of 156 holders
Holding Since
Mar 2025
6 quarters on record
Voting authority
Sole 83%
Shared 17%
None 0%
Common Shares in RIGL Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026MASSACHUSETTS FINANCIAL SERVICES CO /MA/ holds $2,249,676,327 across 65 Biotechnology names. RIGL ranks #30 (0.1% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | ASND |
Ascendis Pharma A/S
|
1,875,301 | $500,180,281 | |
| 2 | RVMD |
Revolution Medicines, Inc.
|
2,012,317 | $376,866,725 | |
| 3 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
423,049 | $210,141,127 | |
| 4 | TECH |
BIO-TECHNE Corp
|
2,746,462 | $194,037,538 | |
| 5 | SRRK |
Scholar Rock Holding Corp
|
2,607,348 | $143,404,140 | |
| 6 | LGND |
Ligand Pharmaceuticals Inc
|
375,762 | $118,774,610 | |
| 7 | ALNY |
Alnylam Pharmaceuticals, Inc.
|
350,560 | $105,529,075 | |
| 8 | BNTX |
BioNTech SE
|
677,708 | $63,060,728 |
All Filings in RIGL
Export CSV
6 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $1,656,379 | 42,341 | Shares | Defined | 2026-08-03 | |
| 2026-03-31 | $1,190,543 | 44,029 | Shares | Defined | 2026-05-14 | |
| 2025-12-31 | $2,269,218 | 52,982 | Shares | Sole | 2026-01-22 | |
| 2025-09-30 | $1,550,614 | 54,734 | Shares | Sole | 2025-10-29 | |
| 2025-06-30 | $957,721 | 51,133 | Shares | Sole | 2025-08-08 | |
| 2025-03-31 | $600,308 | 33,369 | Shares | Sole | 2025-05-02 | |
| No filing history on record for this holder in this stock. | ||||||